Purpose: To evaluate corneal and conjunctival changes after chronic, once-daily dosing of travoprost preserved with sofZia, latanoprost preserved with 0.02% benzalkonium chloride (BAK), or preservative-free artificial tears.
Methods: Thirty New Zealand white rabbits were randomized to receive once-daily instillation of travoprost with sofZia, latanoprost, or preservative-free artificial tears in 1 eye. Corneal epithelial changes were evaluated by transmission electron microscopy and graded on a standard scale by 2 masked observers. Conjunctival inflammation was evaluated by light microscopy after hematoxylin and eosin staining. Lymphocytes were counted in the epithelium and superficial stroma by 2 masked observers and compared among groups.
Results: Corneal tissue treated with preservative-free artificial tears and travoprost with sofZia revealed similar changes under transmission electron microscopy (P = 0.53). Significantly more corneal epithelial damage was noted with latanoprost than travoprost with sofZia (P = 0.0001). The number of lymphocytes in the conjunctival epithelium and stroma was significantly lower in eyes treated with travoprost with sofZia than eyes treated with latanoprost (P = 0.0001). The number of conjunctival lymphocytes was similar among conjunctival specimens exposed to travoprost with sofZia and preservative-free artificial tears (P = 0.65).
Conclusions: Once-daily dosing of travoprost with sofZia produced significantly fewer corneal changes and less conjunctival inflammation than latanoprost preserved with BAK. Corneal and conjunctival changes noted with travoprost with sofZia were similar to those induced by preservative-free artificial tears. Glaucoma medication with high levels of BAK may cause more deleterious effects on the ocular surface than non-BAK-preserved medications. Human studies are needed to better understand the clinical effects of different preservative types and concentrations on the ocular surface.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ICO.0b013e31815cf651 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corneal and Conjunctival Wound-Healing Assays as a Tool for Antiglaucoma Prostaglandin Formulation Characterization.
Front Biosci (Landmark Ed)
May 2022
Institut de la Vision, Sorbonne Université, INSERM, CNRS, IHU Foresight, 75012 Paris, France.
Background: Benzalkonium chloride (BAK)-containing antiglaucoma therapies alter the ocular surface over the long term. We used an scraping model to compare the effects of preserved and unpreserved topical commercial prostaglandins (PGs) in a wound-healing model.
Methods: Standardized mechanical scraping was performed in confluent immortalized human corneal/conjunctival epithelial cell layers.
Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost.
Rom J Ophthalmol
December 2019
Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India.
The topical medications containing benzalkonium chloride (BAK) as preservative is known to induce corneal toxicity and ocular surface disease (OSD) in glaucoma patients. Newer preservatives like SofZia or polyquaternium-1 (Polyquad) have been developed to replace BAK in many medications. The present study aimed at comparing the OSD in glaucoma patients receiving BAK preserved travoprost versus travoprost with polyquad as preservative and controls not receiving any medications.
View Article and Find Full Text PDFThe Effects of Latanoprost With Benzalkonium Chloride Versus Travoprost With SofZia on the Ocular Surface.
Eye Contact Lens
November 2018
Glaucoma Research Center (K.R., S.S.W., M.R.M., L.A.H., L.J.K.), Wills Eye Hospital, Philadelphia, PA; and Cornea Department (C.J.R.), Wills Eye Hospital, Philadelphia, PA; Formerly Glaucoma Research Center (P.I.), Wills Eye Hospital, Philadelphia, PA; Currently Department of Ophthalmology (P.I.), Government Medical College and Hospital, Chandigarh, India.
Purpose: To assess ocular surface changes in participants using latanoprost with benzalkonium chloride (Xalatan) and travoprost with SofZia (Travatan Z).
Methods: In this prospective, open-label, nonrandomized cohort study, participants were classified into two groups: group 1 (n=28) naive to glaucoma therapy, group 2 (n=27) on previous Xalatan monotherapy in both eyes. Both groups started (or continued) Xalatan in the right eye and Travatan Z in the left eye.
Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
J Glaucoma
June 2016
*Department of Ophthalmology, University of Tokyo †Shirato Eye Clinic, Tokyo ‡Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto §Department of Ophthalmology, Ehime University, Ehime ∥Department of Ophthalmology, University of Ryukyus, Okinawa ¶Eguchi Eye Hospital, Hakodate #Department of Ophthalmology, Yokohama City University Medical Center, Yokohama **Yokohama Hodogaya Central Hospital, Yokohama, Japan.
Purpose: To assess the effect of switching 1 eye to topical travoprost 0.004% preserved with SofZia (TRAVATAN Z solution) in patients who had chronic superficial punctate keratitis (SPK) in both eyes treated with benzalkonium chloride-preserved latanoprost 0.005% (XALATAN).
View Article and Find Full Text PDFComparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface.
J Ocul Pharmacol Ther
April 2015
1 Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan .
Purpose: To evaluate some clinically important features of benzalkonium chloride (BAK) toxicity by comparing tafluprost with 0.001% BAK and travoprost preserved with SofZia applied to the ocular surface of the eyes with glaucoma.
Methods: This was a prospective, randomized, observer unmasked, multicenter crossover trial.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!